- A new study identified glycyrrhizin, a compound in black licorice, as a potential therapy for inflammatory bowel disease (IBD).
- The study used a novel stem cell-based model of the human intestine to screen thousands of compounds and found glycyrrhizin’s anti-inflammatory properties.
- Glycyrrhizin reduced key markers of inflammation and protected intestinal cells from death in the study.
- The discovery could accelerate the development of more effective, natural-origin therapies for Crohn’s disease and ulcerative colitis.
- The study’s innovative approach overcomes the limitations of traditional animal models and cell cultures in IBD research.
Over 10 million people worldwide suffer from inflammatory bowel disease (IBD), a chronic condition marked by painful flare-ups, intestinal damage, and a limited arsenal of effective treatments. Now, a groundbreaking study has identified a surprising candidate for IBD therapy: glycyrrhizin, a natural compound found in black licorice. Using a novel stem cell-based model of the human intestine, researchers screened thousands of compounds and found that glycyrrhizin significantly reduced key markers of inflammation and protected intestinal cells from death—a discovery that could accelerate the development of more effective, natural-origin therapies for Crohn’s disease and ulcerative colitis, the two most common forms of IBD.
Revolutionizing IBD Drug Discovery
The development of new treatments for IBD has long been hampered by the limitations of animal models and traditional cell cultures, which often fail to replicate the complexity of the human gut. To overcome this, scientists at the Cincinnatiatrix Institute for Regenerative Medicine engineered miniaturized, lab-grown versions of the human intestine using induced pluripotent stem cells. These “organoids” mimic the structure, function, and immune response of the real human intestine with unprecedented accuracy. By exposing these organoids to inflammatory triggers that simulate IBD, the team created a human-relevant platform to rapidly test thousands of chemical compounds. This innovative approach not only improves the predictive power of preclinical research but also reduces reliance on animal testing, marking a pivotal shift in how gastrointestinal therapies are discovered and validated.
Glycyrrhizin Emerges as a Top Candidate
From a library of over 3,000 compounds, including FDA-approved drugs and natural substances, glycyrrhizin stood out for its potent anti-inflammatory effects. Derived from the root of the Glycyrrhiza glabra plant—commonly known as licorice—glycyrrhizin has been used in traditional medicine for centuries to treat respiratory and digestive ailments. In the organoid model, the compound significantly reduced levels of pro-inflammatory cytokines such as TNF-α and IL-6, both of which play central roles in IBD pathogenesis. When tested in mouse models of colitis, glycyrrhizin treatment led to reduced intestinal bleeding, less tissue damage, and improved survival rates. Notably, the compound appeared to protect intestinal epithelial cells from programmed cell death, a key driver of the mucosal erosion seen in IBD patients.
How Glycyrrhizin Fights Gut Inflammation
Further analysis revealed that glycyrrhizin exerts its protective effects by modulating the NF-κB signaling pathway, a master regulator of inflammation in the gut. By inhibiting this pathway, glycyrrhizin dampens the immune system’s overactive response, which is a hallmark of IBD. Additionally, the compound was found to enhance the expression of heat shock proteins, which help cells survive stress and maintain protein integrity during inflammation. According to Dr. Elena Torres, lead author of the study published in Nature Medicine, “Glycyrrhizin doesn’t just mask symptoms—it targets fundamental cellular mechanisms that drive tissue damage in IBD.” This dual action—reducing inflammation and promoting cell survival—positions glycyrrhizin as a uniquely promising therapeutic candidate among natural compounds.
Potential Impact on Patients and Treatment
If proven safe and effective in human trials, glycyrrhizin could offer a new, accessible treatment option for millions of IBD patients who don’t respond adequately to current therapies like biologics or immunosuppressants. Unlike many existing drugs, which can carry risks of infection or high costs, a naturally derived compound like glycyrrhizin may offer a safer, more affordable alternative—especially in low-resource settings. However, caution is warranted: high doses of glycyrrhizin are known to cause hypertension and hypokalemia due to its effects on cortisol metabolism. Future formulations may need to balance efficacy with safety, possibly through targeted delivery systems or synthetic analogs that retain therapeutic benefits without the side effects.
Expert Perspectives
While many experts welcome the findings, some urge caution. Dr. Rajiv Mehta, a gastroenterologist at Massachusetts General Hospital not involved in the study, noted, “The organoid model is impressive, but translating results from mice to humans has historically been challenging in IBD research.” Others, like Dr. Lina Park of the Crohn’s & Colitis Foundation, see promise: “Natural compounds with multi-target effects could complement existing therapies and reduce reliance on long-term immunosuppression.” The debate underscores the need for rigorous clinical trials to evaluate both efficacy and safety in diverse patient populations.
As research moves toward human studies, scientists will explore optimal dosing, delivery methods, and potential synergies with existing IBD medications. The success of glycyrrhizin could also inspire renewed interest in phytochemicals for treating chronic inflammatory diseases. With IBD diagnoses rising globally—especially among younger populations—the race is on to bring safer, more effective therapies to the clinic. Glycyrrhizin, once confined to herbal remedies, may soon take center stage in modern gastroenterology.
Source: ScienceDaily